Compare AKBA & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | PLBY |
|---|---|---|
| Founded | 2007 | 1953 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 204.4M |
| IPO Year | 2014 | 2020 |
| Metric | AKBA | PLBY |
|---|---|---|
| Price | $1.22 | $1.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $4.67 | $3.00 |
| AVG Volume (30 Days) | ★ 4.1M | 1.0M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | 87.50 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $120,928,000.00 |
| Revenue This Year | N/A | $9.17 |
| Revenue Next Year | N/A | $7.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.13 |
| 52 Week Low | $0.82 | $1.08 |
| 52 Week High | $3.81 | $2.75 |
| Indicator | AKBA | PLBY |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 48.91 |
| Support Level | $1.16 | $1.23 |
| Resistance Level | $1.52 | $1.94 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 7.59 | 77.14 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.